EUVIMEDEUVIMED entdecken
Crossref

Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome

Zvi Laron iD, Haim Werner

Endocrine-Related Cancer · 2023

DOI: 10.1530/erc-22-0394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Zvi Laron und 1 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Laron Syndrome, Human Growth Hormone, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 99 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many clinical and experimental studies have implicated the growth hormone (GH)–insulin-like growth factor (IGF-1) axis with the progression of cancer. The epidemiological finding that patients with Laron syndrome (LS), the best-characterized disease under the spectrum of congenital IGF-1 deficiencies, do not develop cancer is of major scientific and translational relevance. The evasion of LS patients from cancer emphasizes the central role of the GH–IGF-1 system in cancer biology. To identify genes that are differentially expressed in LS and that might provide a biological foundation for cancer protection, we have recently conducted genome-wide profiling of LS patients and normal controls. Analyses were performed on immortalized lymphoblastoid cell lines derived from individual patients. Bioinformatic analyses identified a series of genes that are either over- or under-represented in LS. Differential expression was demonstrated in a number of gene families, including cell cycle, metabolic control, cytokine–cytokine receptor interaction, Jak-STAT and PI3K-AKT signaling, etc. Major differences between LS and controls were also noticed in pathways associated with cell cycle distribution, apoptosis, and autophagy. The identification of novel downstream targets of the GH–IGF-1 network highlights the biological complexity of this hormonal system and sheds light on previously unrecognized mechanistic aspects associated with GH–IGF-1 action in the cancer cell.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Laron SyndromeHuman Growth HormoneNeoplasmsInsulin-Like Growth Factor IHumansPhosphatidylinositol 3-KinasesGrowth HormoneGrowth DisordersHearing Loss, Sensorineural

Stichwörter der Autor:innen

GH receptor (GHR)IGF-1 deficiencyLaron syndromecancer protectiongrowth hormone (GH)growth hormone insensitivityinsulin-like growth factor-1 (IGF-1)

Substanzen

Growth HormoneHuman Growth HormoneInsulin-Like Growth Factor IPhosphatidylinositol 3-KinasesIGF1 protein, human

Autor:innen und Institutionen

  • Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, Petah Tikva, Israel.
  • Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Zvi Laron

Zitieren

APA

Laron, Z., & Werner, H. (2023). Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome. Endocrine-Related Cancer. https://doi.org/10.1530/erc-22-0394

Vancouver

Laron Z, Werner H. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome. Endocrine-Related Cancer. 2023. doi:10.1530/erc-22-0394

BibTeX
@article{Laron2023,
  author = {Laron, Zvi and Werner, Haim},
  title = {Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome},
  journal = {Endocrine-Related Cancer},
  year = {2023},
  doi = {10.1530/erc-22-0394}
}
Kostenlos starten →